BioCentury | Oct 26, 2020
Emerging Company Profile

Serial dealmaker Glick to lead cancer start-up Scorpion with familiar VCs supplying $108M

...holding company, and later housed in the IFM Tre Inc....
BioCentury | Jun 4, 2020
Finance

NodThera parlays interest in inflammasome into Novo Ventures-led $55M series B

...I-O Portfolio” ). After spinning out of IFM Therapeutics Inc., IFM Therapeutics LLC formed the IFM Tre Inc....
BioCentury | Dec 21, 2019
Product Development

China a priority for Novartis’ Narasimhan

...Novartis has engaged in a variety of deal styles. It has acquired Endocyte Inc. and IFM Tre Inc....
BioCentury | Apr 12, 2019
Product Development

NLRP3 early and often

...to join in. Within one year of launching with a $31 million series A round, IFM Tre Inc....
BioCentury | Apr 11, 2019
Targets & Mechanisms

A venture view of biological white space

...target in liver disorders, has compelling potential in neurodegenerative diseases. Last week, Novartis AG acquired IFM Tre Inc....
...NASDAQ:FLDM), South San Francisco, Calif. Foghorn Therapeutics Inc., Cambridge, Mass. Fulcrum Therapeutics Inc., Cambridge, Mass. IFM Tre Inc....
BioCentury | Apr 6, 2019
Finance

Room to rally in 2Q

...IPO from companies working on non-alcoholic steatohepatitis (NASH) programs. On April 1, Novartis AG acquired IFM Tre Inc....
BioCentury | Apr 1, 2019
Company News

Novartis buying IFM inflammasome unit less than a year after launch

...also eligible for up to $1.3 billion in milestones. IFM Therapeutics LLC (Boston, Mass.) launched IFM Tre Inc....
BioCentury | Feb 16, 2019
Emerging Company Profile

NodThera: Inhibiting the inflammasome for NASH

...all have programs in NASH. Inflazome is developing an NLRP3 inhibitor for Parkinson’s disease. The IFM Tre Inc....
BioCentury | Feb 13, 2019
Company News

IFM launches subsidiary for cGAS, STING inhibitors

...antagonists of NLRP3 to treat inflammatory diseases. Those programs were later housed in initial subsidiary IFM Tre Inc....
...protein 173 IFM Therapeutics LLC, Boston, Mass. Business: Autoimmune, Inflammation, Neurology Paul Bonanos IFM Therapeutics Inc. IFM Therapeutics LLC IFM Tre Inc. cGAMP...
BioCentury | Feb 11, 2019
Company News

IFM launches subsidiary for cGAS, STING inhibitors

...antagonists of NLRP3 to treat inflammatory diseases. Those programs were later housed in initial subsidiary IFM Tre Inc....
...family pyrin domain containing 3; STING (TMEM173) - Transmembrane protein 173 Paul Bonanos IFM Therapeutics Inc. IFM Therapeutics LLC IFM Tre Inc. cGAMP...
Items per page:
1 - 10 of 12
BioCentury | Oct 26, 2020
Emerging Company Profile

Serial dealmaker Glick to lead cancer start-up Scorpion with familiar VCs supplying $108M

...holding company, and later housed in the IFM Tre Inc....
BioCentury | Jun 4, 2020
Finance

NodThera parlays interest in inflammasome into Novo Ventures-led $55M series B

...I-O Portfolio” ). After spinning out of IFM Therapeutics Inc., IFM Therapeutics LLC formed the IFM Tre Inc....
BioCentury | Dec 21, 2019
Product Development

China a priority for Novartis’ Narasimhan

...Novartis has engaged in a variety of deal styles. It has acquired Endocyte Inc. and IFM Tre Inc....
BioCentury | Apr 12, 2019
Product Development

NLRP3 early and often

...to join in. Within one year of launching with a $31 million series A round, IFM Tre Inc....
BioCentury | Apr 11, 2019
Targets & Mechanisms

A venture view of biological white space

...target in liver disorders, has compelling potential in neurodegenerative diseases. Last week, Novartis AG acquired IFM Tre Inc....
...NASDAQ:FLDM), South San Francisco, Calif. Foghorn Therapeutics Inc., Cambridge, Mass. Fulcrum Therapeutics Inc., Cambridge, Mass. IFM Tre Inc....
BioCentury | Apr 6, 2019
Finance

Room to rally in 2Q

...IPO from companies working on non-alcoholic steatohepatitis (NASH) programs. On April 1, Novartis AG acquired IFM Tre Inc....
BioCentury | Apr 1, 2019
Company News

Novartis buying IFM inflammasome unit less than a year after launch

...also eligible for up to $1.3 billion in milestones. IFM Therapeutics LLC (Boston, Mass.) launched IFM Tre Inc....
BioCentury | Feb 16, 2019
Emerging Company Profile

NodThera: Inhibiting the inflammasome for NASH

...all have programs in NASH. Inflazome is developing an NLRP3 inhibitor for Parkinson’s disease. The IFM Tre Inc....
BioCentury | Feb 13, 2019
Company News

IFM launches subsidiary for cGAS, STING inhibitors

...antagonists of NLRP3 to treat inflammatory diseases. Those programs were later housed in initial subsidiary IFM Tre Inc....
...protein 173 IFM Therapeutics LLC, Boston, Mass. Business: Autoimmune, Inflammation, Neurology Paul Bonanos IFM Therapeutics Inc. IFM Therapeutics LLC IFM Tre Inc. cGAMP...
BioCentury | Feb 11, 2019
Company News

IFM launches subsidiary for cGAS, STING inhibitors

...antagonists of NLRP3 to treat inflammatory diseases. Those programs were later housed in initial subsidiary IFM Tre Inc....
...family pyrin domain containing 3; STING (TMEM173) - Transmembrane protein 173 Paul Bonanos IFM Therapeutics Inc. IFM Therapeutics LLC IFM Tre Inc. cGAMP...
Items per page:
1 - 10 of 12